In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Otsuka nets Yen198.6bn via its IPO on the Tokyo Stock Exchange

Executive Summary

Otsuka Holdings Co. Ltd., the diversified parent company of Otsuka Pharmaceutical Co. Ltd., has raised Yen198.6bn ($2.3bn) through its oversubscribed initial public offering of 90mm shares at Yen2,100 ($25.16), the lower end of its Yen2,000-2,400 range. About 60% of the shares were sold to overseas investors. Otsuka will trade on the First Section of the Tokyo Stock Exchange.
Deal Industry
  • Diversified
  • In Vitro Diagnostics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies